68 companies. $9.1 billion. Biotech's best first half for venture funding since 2022.


Now the number that didn't make the headline: two-thirds of those rounds went to companies that already had a drug in a human being.


I've spent two decades on the operational side of this industry — sub-investigator, CRO, sponsor. So this is my thoughts:


It isn't "biotech is back."
It's "biotech is buying certainty."


The evidence, as of this month:
→ 76% of H1 venture dollars went into megarounds of $100M+
→ Seed and Series A fell to $2.3B in Q1, down from $3.7B a year earlier. First-time founders are absorbing that entire gap.
→ 21 biotech IPOs have priced in 2026, averaging roughly 55% returns — and nearly every one arrived with Phase 2 data already in hand
→ The August window didn't close. It narrowed on price. Capital rotated into PIPEs and reverse mergers instead.
→ Cell and gene therapy is tracking toward ~$2B again. Its fifth flat year.


Digital health tells the same story in a different accent: $7.4B across 244 deals, where 8% of deals absorbed 45% of the capital. And zero IPOs so far this year.


Here's the part I can't stop thinking about.
When investors were asked what still counts as a moat now that AI is table stakes, the top answer wasn't a model or a dataset.


It was founder domain expertise. People who have actually stood inside the system they're trying to fix.
Capital has stopped paying for possibility. It is paying for proof — clinical proof, operational proof, lived proof.
That is not a downturn. That is a filter.


If you're preclinical, first-time, or building in an unfashionable indication: the money still exists. The bar simply moved from "compelling story" to "de-risked story."

I am happy to discuss with you kow community can help you today!


Know which one you're pitching.

One Story Changes Lives. And it can be yours today!


#healthtech #biotech #venturecapital #clinicaltrials #digitalhealth #founderjourney